We are live on ! Find out more
ACRV icon

Acrivon Therapeutics
ACRV

63 hedge funds and large institutions have $140M invested in Acrivon Therapeutics in 2024 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 18 increasing their positions, 15 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

160% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 5

20% more repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 15

15% more funds holding

Funds holding: 55 → 63 (+8)

0.52% more ownership

Funds ownership: 74.18% → 74.71% (+0.52%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

13% less capital invested

Capital invested by funds: $161M → $140M (-$20.8M)

Holders
63
Holders Change
+8
Holders Change %
+14.55%
% of All Funds
0.83%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
13
Increased
18
Reduced
15
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$1.15M
2
Goldman Sachs
Goldman Sachs
New York
+$286K
3
Vanguard Group
Vanguard Group
Pennsylvania
+$248K
4
UOC
UBS O'Connor
Illinois
+$171K
5
PFCS
Pale Fire Capital SE
Czech Republic
+$111K

Top Sellers

Rank Fund Capital Flow
1
Marshall Wace
Marshall Wace
United Kingdom
-$1.54M
2
EAM
Exome Asset Management
New York
-$817K
3
Millennium Management
Millennium Management
New York
-$278K
4
PCM
Prelude Capital Management
New York
-$264K
5
Citadel Advisors
Citadel Advisors
Florida
-$152K
Name Holding Trade Value Shares
Change 		Change in
Stake
ETC
26
Exchange Traded Concepts
Oklahoma
$122K – – –
RhumbLine Advisers
27
RhumbLine Advisers
Massachusetts
$107K -$36 -5 -0%
American Century Companies
28
American Century Companies
Missouri
$106K +$15.9K +2,186 +14%
TI
29
Trexquant Investment
Connecticut
$102K -$98.2K -13,512 -44%
PFCS
30
Pale Fire Capital SE
Czech Republic
$91.7K +$111K +15,235 New
UBS Group
31
UBS Group
Switzerland
$85.6K +$62.2K +8,555 +151%
N
32
Nuveen
North Carolina
$80.7K -$89.9K -12,377 -48%
MG
33
Marex Group
$79.4K – – –
Citigroup
34
Citigroup
New York
$74.2K +$8.11K +1,116 +10%
CC
35
Corton Capital
Ontario, Canada
$73.2K +$88.4K +12,159 New
WIA
36
Wealthedge Investment Advisors
New York
$65.4K +$78.9K +10,857 New
AWM
37
AAF Wealth Management
Massachusetts
$64.3K – – –
Wells Fargo
38
Wells Fargo
California
$41.7K +$11K +1,511 +28%
Mirae Asset Global ETFs Holdings
39
Mirae Asset Global ETFs Holdings
Hong Kong
$40.8K +$2.21K +304 +5%
CUAMC
40
China Universal Asset Management Company
China
$39.7K +$48K +6,602 New
CF
41
Corebridge Financial
Texas
$35.4K -$3.22K -443 -7%
Fidelity Investments
42
Fidelity Investments
Massachusetts
$17.7K +$2.56K +352 +14%
New York State Common Retirement Fund
43
New York State Common Retirement Fund
New York
$13.9K – – –
BNP Paribas Financial Markets
44
BNP Paribas Financial Markets
France
$11.7K +$14.1K +1,941 New
TRCT
45
Tower Research Capital (TRC)
New York
$10.6K -$21.7K -2,989 -63%
Royal Bank of Canada
46
Royal Bank of Canada
Ontario, Canada
$10K +$2.62K +361 +28%
Mirae Asset Global Investments
47
Mirae Asset Global Investments
South Korea
$6.14K +$7.54K +1,038 New
California State Teachers Retirement System (CalSTRS)
48
California State Teachers Retirement System (CalSTRS)
California
$5.15K – – –
Legal & General Group
49
Legal & General Group
United Kingdom
$5.08K – – –
SO
50
STRS Ohio
Ohio
$4.82K – – –
1
2
3

ACRV Hedge Fund Activity: Q4 2024 in Review

63 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Acrivon Therapeutics (ACRV) for Q4 2024, worth a combined $140M — down 13% from $161M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new ACRV positions and 5 closed out — a net gain of 8 holders — while 18 added to existing stakes and 15 trimmed.

The largest buyer was BlackRock, adding an estimated $1.15M. The largest seller was Marshall Wace, cutting an estimated $1.54M.

  • 63 institutional investors held Acrivon Therapeutics (ACRV) as of Q4 2024, up from 55 in Q3 2024.
  • Funds reported $140M of Acrivon Therapeutics stock for Q4 2024, down 13% quarter-over-quarter.
  • 13 funds opened new Acrivon Therapeutics positions in Q4 2024 and 5 closed out, a net change of +8 holders.
  • The largest Acrivon Therapeutics buyer in Q4 2024 was BlackRock, an estimated $1.15M added.
  • The largest Acrivon Therapeutics seller in Q4 2024 was Marshall Wace, an estimated $1.54M sold.

Based on aggregated 13F filings for Q4 2024.